Shore Capital Reiterates Buy Rating for AstraZeneca (LON:AZN)

Shore Capital reissued their buy rating on shares of AstraZeneca (LON:AZN) in a research report sent to investors on Monday, MarketBeat reports.

AZN has been the topic of several other reports. Berenberg Bank reaffirmed a buy rating on shares of AstraZeneca in a research report on Wednesday, March 13th. Deutsche Bank Aktiengesellschaft reaffirmed a sell rating on shares of AstraZeneca in a research report on Tuesday, March 12th. JPMorgan Chase & Co. reaffirmed an overweight rating on shares of AstraZeneca in a research report on Thursday, April 4th. UBS Group cut their price target on AstraZeneca from £107 ($133.20) to GBX 9,900 ($123.24) and set a sell rating on the stock in a research report on Monday, February 12th. Finally, Jefferies Financial Group restated a hold rating and set a £110 ($136.94) target price on shares of AstraZeneca in a research report on Friday, February 16th. One research analyst has rated the stock with a sell rating, two have given a hold rating and six have given a buy rating to the company. Based on data from MarketBeat.com, the company has a consensus rating of Moderate Buy and a consensus price target of £115.43 ($143.69).

AstraZeneca Price Performance

Shares of AZN opened at £109.14 ($135.86) on Monday. The business’s 50-day moving average is £103.71 and its two-hundred day moving average is £104.29. The company has a market capitalization of £169.17 billion, a P/E ratio of 3,601.98, a P/E/G ratio of 0.89 and a beta of 0.19. The company has a debt-to-equity ratio of 75.70, a quick ratio of 0.59 and a current ratio of 0.82. AstraZeneca has a fifty-two week low of GBX 9,461 ($117.78) and a fifty-two week high of £123.48 ($153.72).

AstraZeneca Increases Dividend

The firm also recently announced a dividend, which was paid on Monday, March 25th. Stockholders of record on Thursday, February 22nd were given a dividend of GBX 156 ($1.94) per share. The ex-dividend date was Thursday, February 22nd. This is a boost from AstraZeneca’s previous dividend of $71.80. This represents a dividend yield of 1.49%. AstraZeneca’s dividend payout ratio (DPR) is 7,524.75%.

About AstraZeneca

AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines. The company's marketed products include Tagrisso, Imfinzi, Lynparza, Calquence, Enhertu, Orpathys, Truqap, Zoladex, Faslodex, Farxiga, Brilinta, Lokelma, Roxadustat, Andexxa, Crestor, Seloken, Onglyza, Bydureon, Fasenra, Breztri, Symbicort, Saphnelo, Tezspire, Pulmicort, Bevespi, and Daliresp for cardiovascular, renal, metabolism, and oncology.